Clinical experience with tigecycline in the treatment of hospital-acquired pneumonia caused by multidrug resistant Acinetobacter baumannii

BACKGROUND: Tigecycline, with broad in vitro antibacterial activity, has been widely used off-label for nosocomial pneumonia caused by multi-drug resistant Acinetobacter baumannii (MDRAB). However, many concerns have been raised about the efficacy of tigecycline treatment as the inconsistent results...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:BMC Pharmacol Toxicol
Hlavní autoři: Zhou, Yangang, Chen, Xumin, Xu, Ping, Zhu, Yan, Wang, Kuangguo, Xiang, Daxiong, Wang, Feng, Banh, Hoan Linh
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2019
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6482491/
https://ncbi.nlm.nih.gov/pubmed/31023357
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40360-019-0300-3
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky